

# The American Journal of Clinical Nutrition

## Diet, blood pressure and heart disease - precision nutrition approaches to understand response to diet and predict disease risk --Manuscript Draft--

<b>Manuscript Number:</b>	AJCN-D-21-01203R1
<b>Full Title:</b>	Diet, blood pressure and heart disease - precision nutrition approaches to understand response to diet and predict disease risk
<b>Article Type:</b>	Invited Editorial
<b>Corresponding Author:</b>	Baukje de Roos University of Aberdeen Aberdeen, UNITED KINGDOM
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	University of Aberdeen
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Baukje de Roos
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Baukje de Roos
<b>Order of Authors Secondary Information:</b>	
<b>Manuscript Region of Origin:</b>	UNITED KINGDOM
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
<b>Number of words:</b>	962
<b>Has this manuscript been posted to a preprint server?</b>	No

1 **Diet, blood pressure and heart disease - precision nutrition approaches to**  
2 **understand response to diet and predict disease risk**

3

4 Baukje de Roos, MSc PhD

5

6 Rowett Institute, University of Aberdeen

7 Foresterhill, Aberdeen AB54 4RR, United Kingdom

8 Phone: +44 (0)1224 438636

9 E-mail: [b.deroos@abdn.ac.uk](mailto:b.deroos@abdn.ac.uk)

10

11 The author has no conflict of interest to report. Baukje de Roos is a **member of the**  
12 **Editorial Board of** The American Journal of Clinical Nutrition. The work of Baukje de  
13 Roos is supported by the Scottish Government's Rural and Environment Science  
14 and Analytical Services (RESAS).

15 Before the start of the epidemiological investigations of the Framingham study in  
16 1949, hypertension was considered a benign condition. As blood pressure was likely  
17 to increase with age, high blood pressure was considered normal in the elderly. It  
18 was therefore deemed appropriate to '*ignore labile and systolic elevations of blood*  
19 *pressure*' (1). Seventy years later, we have learned that hypertension risk does not  
20 diminish with age, and stratified risks have been characterized for different  
21 population and age groups (1). Hypertension is currently considered a major global  
22 public health problem, with increased systolic and diastolic blood pressure  
23 representing one of our most important risk factors for atherosclerotic cardiovascular  
24 disease (1). We have also learned that the risk and management of hypertension  
25 can be significantly improved by lifestyle and diet. Dietary patterns such as the  
26 Dietary Approaches to Stop Hypertension (DASH), Nordic and Mediterranean diets,  
27 generally rich in fruit, vegetables, whole grains, legumes, seeds, nuts, fish and low-  
28 fat dairy foods, and low in red meat, sugar-sweetened foods/beverages and alcohol,  
29 have been shown to significantly lower average levels of systolic and diastolic blood  
30 pressure in populations in randomized controlled trials (2). But many of these  
31 randomized controlled trials have also demonstrated that less than half of the  
32 population may effectively respond to a dietary intervention (3). To elucidate who  
33 responds to which dietary interventions, and understand why, it is imperative to  
34 advance the application of precision nutrition approaches.

35 In the past decades, a range of novel technological tools, including metabolomics,  
36 transcriptomics, proteomics, and metagenomics, have been developed to investigate  
37 the interactions between nutrition and the host metabolome, genome and proteome.  
38 These studies have already played an important role in enhancing our understanding  
39 of the actions of diets, foods and nutrients on the cellular level (4). Increasingly,

40 nutrigenomic approaches are also being applied to identify existing and novel  
41 efficacy biomarkers that can be used to improve the prediction of (early) disease  
42 development, or to monitor how populations and individuals respond to diets. An  
43 elegant example of this has been published in the current issue of the American  
44 Journal of Clinical Nutrition (5), where a combination of baseline and postprandial  
45 clinical and metabolomics markers were analyzed in healthy subjects with and  
46 without subclinical atherosclerosis in an Asian population. Models were trained using  
47 a range of methodologies, to produce a novel model based on postprandial systolic  
48 or diastolic blood pressure and age to detect subclinical atherosclerosis in a low  
49 coronary heart disease risk group (5). This study highlights the importance of finding  
50 more sensitive biomarkers that can detect early-stage disease development. This is  
51 a stage when nutrition could make a significant impact, but where mechanistic  
52 pathways are often poorly understood. It also highlights the importance of including  
53 postprandial measurements, including postprandial blood pressure, since monitoring  
54 metabolic changes after a glucose, lipid or mixed meal challenge, rather than relying  
55 on baseline or fasting measurements alone, may deliver better predictors of health or  
56 disease status, especially in low-risk populations (6).

57 From a nutritional perspective, an important next step would be the identification of  
58 existing or novel efficacy biomarkers that can help to predict which individuals or  
59 population groups may respond more or less favorably to a specific diet. Thus far,  
60 the variability in blood pressure (or indeed other cardiovascular risk factors or  
61 biomarkers of disease) between and within subjects has often obscured the precise  
62 relationship between diets and clinical disease outcomes in randomized controlled  
63 trials. However, across studies, an important finding has been that the inter-  
64 individual variability in such risk factors is often higher than their intra-individual

65 variability, and this concept could be exploited when trying to understand individual  
66 responsiveness to interventions in precision nutrition (4). Indeed, for some trial  
67 designs in the field of precision nutrition, such as N-of-1 studies, the capture of  
68 variation in, for example, blood pressure or dietary intake outcomes, by taking  
69 multiple measurements over time, will allow the development of unique regression  
70 models that consider the influence of individualized predictors on a health or disease  
71 outcomes (7). Data from longitudinal studies that include postprandial measurements  
72 (to catch the phenotypic flexibility of individuals as an early marker of disease  
73 status), and those that exploit metabolomics platforms (to expand the number of  
74 clinical and biochemical outcomes), in hundreds rather than tens of subjects (to have  
75 sufficient statistical power for model development, particularly when considering  
76 many candidate biomarkers), will be instrumental in enabling the examination of  
77 individual responsiveness when further developing the field of precision nutrition (4).  
78 Provided we are able to take enough measurements on the individual level, and  
79 develop accurate and sophisticated prediction models on the basis of well-powered,  
80 large scale studies, we may be able to predict, with reasonable accuracy, whether a  
81 given individual will respond favorably to a specific diet.

82 The NIH has established a timely vision for the research field of precision nutrition to  
83 develop more precise, targeted and individualized dietary interventions and  
84 guidelines (8). An aspiration could be that in the future, precision nutrition  
85 approaches may enable the identification of dietary interventions which, for certain  
86 individuals or population groups, may be equally if not more effective than a  
87 mainstream pharmacological intervention to modulate disease risk. This is not an  
88 inconceivable scenario. For blood pressure, for example, a series of studies have  
89 already proven that intervention with riboflavin, a cheap and readily available B

90 vitamin, lowers blood pressure in cardiovascular disease patients that are  
91 homogenous for the MTHFR 677C→T polymorphism. These patients have  
92 significantly higher baseline blood pressure levels, and intervention with riboflavin  
93 will thus decrease their genetic risk of hypertension. Interestingly, in this group,  
94 riboflavin supplementation works, on average, as effectively as administering ACE  
95 inhibitors (9). Such findings may shift the way we consume diets and nutrients, and  
96 the way we provide (preventative) healthcare in relation to blood pressure and other  
97 conditions.

98

## 99 **References**

100

101 (1) Kannel WB. Fifty years of Framingham Study contributions to understanding  
102 hypertension. *Journal of Human Hypertension* 2000;14(2):83–90.

103 (2) Ndanuko RN, Tapsell LC, Charlton KE, Neale EP, Batterham MJ. Dietary  
104 patterns and blood pressure in adults: a systematic review and meta-analysis of  
105 randomized controlled trials. *Advances in Nutrition* 2016;7(1):76–89.

106 (3) Tierney AC, McMonagle J, Shaw DI, Gulseth HL, Helal O, Saris WH, Paniagua  
107 JA, Golabek-Leszczynska I, Defoort C, Williams CM, et al. Effects of dietary fat  
108 modification on insulin sensitivity and on other risk factors of the metabolic  
109 syndrome—LIPGENE: A European randomized dietary intervention study.  
110 *International Journal of Obesity* 2011;35(6):800–809.

111 (4) Brennan L, de Roos B. Nutrigenomics: lessons learned and future  
112 perspectives. *American Journal of Clinical Nutrition* 2021;113(3):503–516.

- 113 (5) Valsesia A, Egli L, Bosco N, Magkos F, Ching Kong S, Sun L, Jen Goh H,  
114 Weiting H, Arigoni F, Khee-Shing Leow, et al. Clinical and omics-based models  
115 of subclinical atherosclerosis in healthy Chinese adults: A cross-sectional  
116 study. *American Journal of Clinical Nutrition* 2021;[tbc].
- 117 (6) Krug S, Kastenmüller G, Stücker F, Rist MJ, Skurk T, Sailer M, Raffler J,  
118 Römisch-Margl W, Adamski J, Prehn C, et al. The dynamic range of the human  
119 metabolome revealed by challenges. *FASEB Journal* 2012;26(6):2607– 2619.
- 120 (7) Potter T, Vieira R and de Roos B. Perspective: Application of N-of-1 Methods in  
121 Personalized Nutrition Research. *Advances in Nutrition* 2021;12(3):579-589.
- 122 (8) 2020–2030 strategic plan for NIH nutrition research: A report of the NIH  
123 Nutrition Research Task Force. NIH; 2020 [Internet]. Available form:  
124 <https://www.niddk.nih.gov/about-niddk/strategic-plans-reports>.
- 125 (9) Wilson CP, Ward M, McNulty H, Strain JJ, Trouton TG, Horigan G, Purvis J,  
126 Scott JM. Riboflavin offers a targeted strategy for managing hypertension in  
127 patients with the MTHFR 677TT genotype: a 4-y follow-up. *American Journal of*  
128 *Clinical Nutrition* 2012;95(3):766-72.



Click here to access/download

**Manuscript for production**

no changes marked

EDiet blood pressure and heart disease.docx

